Form 4: Amicus Therapeutics CEO Bradley Campbell Reports Stock Transactions

Amicus Therapeutics' CEO, Bradley Campbell, reports acquisition of shares through performance-based restricted stock units (PRSUs) and disposition of shares to cover tax obligations.

Summary

• Bradley L Campbell, the President and CEO of Amicus Therapeutics, reported changes in beneficial ownership of the company's stock on February 11, 2025.
• He acquired 137,075 shares of common stock related to the achievement of 2022 PRSUs, granted by the Board of Directors, at a price of $0.
• He also disposed of 70,711 shares of common stock at a price of $9.57, likely to cover tax obligations.
• Following these transactions, Campbell directly owns 1,150,657 shares of Amicus Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The acquisition of shares through PRSUs is positive, but the sale of shares to cover taxes is a normal occurrence and doesn't necessarily indicate a negative outlook.

Positives

• The acquisition of shares through PRSUs suggests that performance targets were met, which could be viewed positively.

Negatives

• The disposal of shares, while likely for tax obligations, could be interpreted negatively by some investors if they believe the CEO is reducing their stake in the company.

Risks

• There are no specific risks mentioned in this document.
• However, investor sentiment can be influenced by insider transactions, so it's important to monitor market reaction.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's confidence in the company's prospects.

Stakeholder Impact

• The transactions could have a minor impact on shareholders depending on how they interpret the CEO's actions.

Key Dates